Global Migraine

Migraine Comprehensive Study by Type (Acute treatment, - Triptans, - Ergot Alkaloids, - Non-specific drugs, Preventive/ Prophylactic treatment, - Anticonvulsants, - Antidepressants, - Beta Blockers, - Others), Application (Episodic migraine, Chronic migraine, Migraine with Aura, Migraine without Aura, Others), Distribution Channels (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others) Players and Region - Global Market Outlook to 2032

Migraine Market by XX Submarkets | Forecast Years 2025-2032  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Migraine
Migraine is a common neurological disorder characterized by repeated attacks of intense throbbing pain in the head. Headaches are often unilateral and can last four hours to three days. The pain is often associated with other symptoms, such as nausea, vomiting, increased sensitivity to light (photophobia), increased sensitivity to sound (phonophobia), numbness or tingling in the legs or feet, sweating, and diarrhea. Migraines are more common in women, with 17.0% of women reporting attacks each year compared to 6.0% of men. The majority of currently available drugs are approved for the acute form of the disease, led by generic triptans as first-line therapy. The market saw a shift in terms of strong research and development with the introduction of CGRP-based therapies and the entry of new drug classes such as Ditans, Gepants, and the reformulation of triptans for chronic and episodic migraines.

AttributesDetails
Study Period2020-2032
Base Year2024
UnitValue (USD Million)


Global migraine is a fragmented market due to the presence of various players. The players are focusing on investing more planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Amgen Inc. (United States), AstraZeneca (United Kingdom), Bristol-Myers Squibb Company (United States), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (United States), Sanofi (France), Merck KGaA (Germany), Eli Lilly and Company (United States), Johnson & Johnson Services, Inc. (United States), AbbVie Inc. (United States) and Gilead Sciences, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Alder Biopharmaceuticals (United States), BioHaven Pharmaceutical Holding Company Ltd. (United States), AOBiome therapeutics (United States), Allodynic therapeutics (United States) and Zosano Pharma Corp (United States).

Segmentation Overview
AMA Research has segmented the market of Global Migraine market by Type (Acute treatment, - Triptans, - Ergot Alkaloids, - Non-specific drugs, Preventive/ Prophylactic treatment, - Anticonvulsants, - Antidepressants, - Beta Blockers and - Others), Application (Episodic migraine, Chronic migraine, Migraine with Aura, Migraine without Aura and Others) and Region.



On the basis of geography, the market of Migraine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channels, the sub-segment i.e. Retail Pharmacies will boost the Migraine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The Increased Prescription of Calcitonin Gene-Related Peptide (CGRP) Antagonists, Gepants, and Monoclonal Antibodies (Mabs) As a Preventive Migraine Treatment

Market Growth Drivers:
Increase in prevalence of Migraine, Growing Female Population and Rising awareness about Migraine Treatment and Prevention among Patients

Challenges:
The High Usage of Generic Products

Restraints:
Side Effect of Migraine Drugs and The Patent Expiration of Medicines Will Lead To Cheap Generics Flooding the Market and Negatively Impacting the Branded Sales

Opportunities:
Emerging Migraine Therapies and Growth Opportunities in Emerging Economies

Market Leaders and their expansionary development strategies
In September 2022, Roche had signed a definitive merger agreement for the acquisition of US-based biopharmaceutical company Good Therapeutics for an upfront payment of USD 250 million in cash. Good Therapeutics focuses on the development of PD-1-regulated IL-2 drugs that are based on innovative conditionally active drug technology.
In September 2022, Axsome Therapeutics enrolled the first patient in a phase 3 trial of AXS-07 for the acute treatment of migraine.


Key Target Audience
Migraine Drug Producers, Healthcare Sector, Regulatory Bodies, Potential Investors, Research and Development Institutes and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Acute treatment
  • - Triptans
  • - Ergot Alkaloids
  • - Non-specific drugs
  • Preventive/ Prophylactic treatment
  • - Anticonvulsants
  • - Antidepressants
  • - Beta Blockers
  • - Others
By Application
  • Episodic migraine
  • Chronic migraine
  • Migraine with Aura
  • Migraine without Aura
  • Others
By Distribution Channels
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in prevalence of Migraine
      • 3.2.2. Growing Female Population
      • 3.2.3. Rising awareness about Migraine Treatment and Prevention among Patients
    • 3.3. Market Challenges
      • 3.3.1. The High Usage of Generic Products
    • 3.4. Market Trends
      • 3.4.1. The Increased Prescription of Calcitonin Gene-Related Peptide (CGRP) Antagonists, Gepants, and Monoclonal Antibodies (Mabs) As a Preventive Migraine Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Migraine, by Type, Application, Distribution Channels and Region (value) (2019-2024)
    • 5.1. Introduction
    • 5.2. Global Migraine (Value)
      • 5.2.1. Global Migraine by: Type (Value)
        • 5.2.1.1. Acute treatment
        • 5.2.1.2. - Triptans
        • 5.2.1.3. - Ergot Alkaloids
        • 5.2.1.4. - Non-specific drugs
        • 5.2.1.5. Preventive/ Prophylactic treatment
        • 5.2.1.6. - Anticonvulsants
        • 5.2.1.7. - Antidepressants
        • 5.2.1.8. - Beta Blockers
        • 5.2.1.9. - Others
      • 5.2.2. Global Migraine by: Application (Value)
        • 5.2.2.1. Episodic migraine
        • 5.2.2.2. Chronic migraine
        • 5.2.2.3. Migraine with Aura
        • 5.2.2.4. Migraine without Aura
        • 5.2.2.5. Others
      • 5.2.3. Global Migraine by: Distribution Channels (Value)
        • 5.2.3.1. Retail Pharmacies
        • 5.2.3.2. Hospital Pharmacies
        • 5.2.3.3. Online Pharmacies
        • 5.2.3.4. Others
      • 5.2.4. Global Migraine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Migraine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2024)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bristol-Myers Squibb Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck KGaA (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson Services, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. AbbVie Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Gilead Sciences, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Migraine Sale, by Type, Application, Distribution Channels and Region (value) (2027-2032)
    • 7.1. Introduction
    • 7.2. Global Migraine (Value)
      • 7.2.1. Global Migraine by: Type (Value)
        • 7.2.1.1. Acute treatment
        • 7.2.1.2. - Triptans
        • 7.2.1.3. - Ergot Alkaloids
        • 7.2.1.4. - Non-specific drugs
        • 7.2.1.5. Preventive/ Prophylactic treatment
        • 7.2.1.6. - Anticonvulsants
        • 7.2.1.7. - Antidepressants
        • 7.2.1.8. - Beta Blockers
        • 7.2.1.9. - Others
      • 7.2.2. Global Migraine by: Application (Value)
        • 7.2.2.1. Episodic migraine
        • 7.2.2.2. Chronic migraine
        • 7.2.2.3. Migraine with Aura
        • 7.2.2.4. Migraine without Aura
        • 7.2.2.5. Others
      • 7.2.3. Global Migraine by: Distribution Channels (Value)
        • 7.2.3.1. Retail Pharmacies
        • 7.2.3.2. Hospital Pharmacies
        • 7.2.3.3. Online Pharmacies
        • 7.2.3.4. Others
      • 7.2.4. Global Migraine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Migraine: by Type(USD Million)
  • Table 2. Migraine Acute treatment , by Region USD Million (2019-2024)
  • Table 3. Migraine - Triptans , by Region USD Million (2019-2024)
  • Table 4. Migraine - Ergot Alkaloids , by Region USD Million (2019-2024)
  • Table 5. Migraine - Non-specific drugs , by Region USD Million (2019-2024)
  • Table 6. Migraine Preventive/ Prophylactic treatment , by Region USD Million (2019-2024)
  • Table 7. Migraine - Anticonvulsants , by Region USD Million (2019-2024)
  • Table 8. Migraine - Antidepressants , by Region USD Million (2019-2024)
  • Table 9. Migraine - Beta Blockers , by Region USD Million (2019-2024)
  • Table 10. Migraine - Others , by Region USD Million (2019-2024)
  • Table 11. Migraine: by Application(USD Million)
  • Table 12. Migraine Episodic migraine , by Region USD Million (2019-2024)
  • Table 13. Migraine Chronic migraine , by Region USD Million (2019-2024)
  • Table 14. Migraine Migraine with Aura , by Region USD Million (2019-2024)
  • Table 15. Migraine Migraine without Aura , by Region USD Million (2019-2024)
  • Table 16. Migraine Others , by Region USD Million (2019-2024)
  • Table 17. Migraine: by Distribution Channels(USD Million)
  • Table 18. Migraine Retail Pharmacies , by Region USD Million (2019-2024)
  • Table 19. Migraine Hospital Pharmacies , by Region USD Million (2019-2024)
  • Table 20. Migraine Online Pharmacies , by Region USD Million (2019-2024)
  • Table 21. Migraine Others , by Region USD Million (2019-2024)
  • Table 22. South America Migraine, by Country USD Million (2019-2024)
  • Table 23. South America Migraine, by Type USD Million (2019-2024)
  • Table 24. South America Migraine, by Application USD Million (2019-2024)
  • Table 25. South America Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 26. Brazil Migraine, by Type USD Million (2019-2024)
  • Table 27. Brazil Migraine, by Application USD Million (2019-2024)
  • Table 28. Brazil Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 29. Argentina Migraine, by Type USD Million (2019-2024)
  • Table 30. Argentina Migraine, by Application USD Million (2019-2024)
  • Table 31. Argentina Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 32. Rest of South America Migraine, by Type USD Million (2019-2024)
  • Table 33. Rest of South America Migraine, by Application USD Million (2019-2024)
  • Table 34. Rest of South America Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 35. Asia Pacific Migraine, by Country USD Million (2019-2024)
  • Table 36. Asia Pacific Migraine, by Type USD Million (2019-2024)
  • Table 37. Asia Pacific Migraine, by Application USD Million (2019-2024)
  • Table 38. Asia Pacific Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 39. China Migraine, by Type USD Million (2019-2024)
  • Table 40. China Migraine, by Application USD Million (2019-2024)
  • Table 41. China Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 42. Japan Migraine, by Type USD Million (2019-2024)
  • Table 43. Japan Migraine, by Application USD Million (2019-2024)
  • Table 44. Japan Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 45. India Migraine, by Type USD Million (2019-2024)
  • Table 46. India Migraine, by Application USD Million (2019-2024)
  • Table 47. India Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 48. South Korea Migraine, by Type USD Million (2019-2024)
  • Table 49. South Korea Migraine, by Application USD Million (2019-2024)
  • Table 50. South Korea Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 51. Taiwan Migraine, by Type USD Million (2019-2024)
  • Table 52. Taiwan Migraine, by Application USD Million (2019-2024)
  • Table 53. Taiwan Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 54. Australia Migraine, by Type USD Million (2019-2024)
  • Table 55. Australia Migraine, by Application USD Million (2019-2024)
  • Table 56. Australia Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 57. Rest of Asia-Pacific Migraine, by Type USD Million (2019-2024)
  • Table 58. Rest of Asia-Pacific Migraine, by Application USD Million (2019-2024)
  • Table 59. Rest of Asia-Pacific Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 60. Europe Migraine, by Country USD Million (2019-2024)
  • Table 61. Europe Migraine, by Type USD Million (2019-2024)
  • Table 62. Europe Migraine, by Application USD Million (2019-2024)
  • Table 63. Europe Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 64. Germany Migraine, by Type USD Million (2019-2024)
  • Table 65. Germany Migraine, by Application USD Million (2019-2024)
  • Table 66. Germany Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 67. France Migraine, by Type USD Million (2019-2024)
  • Table 68. France Migraine, by Application USD Million (2019-2024)
  • Table 69. France Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 70. Italy Migraine, by Type USD Million (2019-2024)
  • Table 71. Italy Migraine, by Application USD Million (2019-2024)
  • Table 72. Italy Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 73. United Kingdom Migraine, by Type USD Million (2019-2024)
  • Table 74. United Kingdom Migraine, by Application USD Million (2019-2024)
  • Table 75. United Kingdom Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 76. Netherlands Migraine, by Type USD Million (2019-2024)
  • Table 77. Netherlands Migraine, by Application USD Million (2019-2024)
  • Table 78. Netherlands Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 79. Rest of Europe Migraine, by Type USD Million (2019-2024)
  • Table 80. Rest of Europe Migraine, by Application USD Million (2019-2024)
  • Table 81. Rest of Europe Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 82. MEA Migraine, by Country USD Million (2019-2024)
  • Table 83. MEA Migraine, by Type USD Million (2019-2024)
  • Table 84. MEA Migraine, by Application USD Million (2019-2024)
  • Table 85. MEA Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 86. Middle East Migraine, by Type USD Million (2019-2024)
  • Table 87. Middle East Migraine, by Application USD Million (2019-2024)
  • Table 88. Middle East Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 89. Africa Migraine, by Type USD Million (2019-2024)
  • Table 90. Africa Migraine, by Application USD Million (2019-2024)
  • Table 91. Africa Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 92. North America Migraine, by Country USD Million (2019-2024)
  • Table 93. North America Migraine, by Type USD Million (2019-2024)
  • Table 94. North America Migraine, by Application USD Million (2019-2024)
  • Table 95. North America Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 96. United States Migraine, by Type USD Million (2019-2024)
  • Table 97. United States Migraine, by Application USD Million (2019-2024)
  • Table 98. United States Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 99. Canada Migraine, by Type USD Million (2019-2024)
  • Table 100. Canada Migraine, by Application USD Million (2019-2024)
  • Table 101. Canada Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 102. Mexico Migraine, by Type USD Million (2019-2024)
  • Table 103. Mexico Migraine, by Application USD Million (2019-2024)
  • Table 104. Mexico Migraine, by Distribution Channels USD Million (2019-2024)
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Migraine: by Type(USD Million)
  • Table 118. Migraine Acute treatment , by Region USD Million (2027-2032)
  • Table 119. Migraine - Triptans , by Region USD Million (2027-2032)
  • Table 120. Migraine - Ergot Alkaloids , by Region USD Million (2027-2032)
  • Table 121. Migraine - Non-specific drugs , by Region USD Million (2027-2032)
  • Table 122. Migraine Preventive/ Prophylactic treatment , by Region USD Million (2027-2032)
  • Table 123. Migraine - Anticonvulsants , by Region USD Million (2027-2032)
  • Table 124. Migraine - Antidepressants , by Region USD Million (2027-2032)
  • Table 125. Migraine - Beta Blockers , by Region USD Million (2027-2032)
  • Table 126. Migraine - Others , by Region USD Million (2027-2032)
  • Table 127. Migraine: by Application(USD Million)
  • Table 128. Migraine Episodic migraine , by Region USD Million (2027-2032)
  • Table 129. Migraine Chronic migraine , by Region USD Million (2027-2032)
  • Table 130. Migraine Migraine with Aura , by Region USD Million (2027-2032)
  • Table 131. Migraine Migraine without Aura , by Region USD Million (2027-2032)
  • Table 132. Migraine Others , by Region USD Million (2027-2032)
  • Table 133. Migraine: by Distribution Channels(USD Million)
  • Table 134. Migraine Retail Pharmacies , by Region USD Million (2027-2032)
  • Table 135. Migraine Hospital Pharmacies , by Region USD Million (2027-2032)
  • Table 136. Migraine Online Pharmacies , by Region USD Million (2027-2032)
  • Table 137. Migraine Others , by Region USD Million (2027-2032)
  • Table 138. South America Migraine, by Country USD Million (2027-2032)
  • Table 139. South America Migraine, by Type USD Million (2027-2032)
  • Table 140. South America Migraine, by Application USD Million (2027-2032)
  • Table 141. South America Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 142. Brazil Migraine, by Type USD Million (2027-2032)
  • Table 143. Brazil Migraine, by Application USD Million (2027-2032)
  • Table 144. Brazil Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 145. Argentina Migraine, by Type USD Million (2027-2032)
  • Table 146. Argentina Migraine, by Application USD Million (2027-2032)
  • Table 147. Argentina Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 148. Rest of South America Migraine, by Type USD Million (2027-2032)
  • Table 149. Rest of South America Migraine, by Application USD Million (2027-2032)
  • Table 150. Rest of South America Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 151. Asia Pacific Migraine, by Country USD Million (2027-2032)
  • Table 152. Asia Pacific Migraine, by Type USD Million (2027-2032)
  • Table 153. Asia Pacific Migraine, by Application USD Million (2027-2032)
  • Table 154. Asia Pacific Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 155. China Migraine, by Type USD Million (2027-2032)
  • Table 156. China Migraine, by Application USD Million (2027-2032)
  • Table 157. China Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 158. Japan Migraine, by Type USD Million (2027-2032)
  • Table 159. Japan Migraine, by Application USD Million (2027-2032)
  • Table 160. Japan Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 161. India Migraine, by Type USD Million (2027-2032)
  • Table 162. India Migraine, by Application USD Million (2027-2032)
  • Table 163. India Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 164. South Korea Migraine, by Type USD Million (2027-2032)
  • Table 165. South Korea Migraine, by Application USD Million (2027-2032)
  • Table 166. South Korea Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 167. Taiwan Migraine, by Type USD Million (2027-2032)
  • Table 168. Taiwan Migraine, by Application USD Million (2027-2032)
  • Table 169. Taiwan Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 170. Australia Migraine, by Type USD Million (2027-2032)
  • Table 171. Australia Migraine, by Application USD Million (2027-2032)
  • Table 172. Australia Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 173. Rest of Asia-Pacific Migraine, by Type USD Million (2027-2032)
  • Table 174. Rest of Asia-Pacific Migraine, by Application USD Million (2027-2032)
  • Table 175. Rest of Asia-Pacific Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 176. Europe Migraine, by Country USD Million (2027-2032)
  • Table 177. Europe Migraine, by Type USD Million (2027-2032)
  • Table 178. Europe Migraine, by Application USD Million (2027-2032)
  • Table 179. Europe Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 180. Germany Migraine, by Type USD Million (2027-2032)
  • Table 181. Germany Migraine, by Application USD Million (2027-2032)
  • Table 182. Germany Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 183. France Migraine, by Type USD Million (2027-2032)
  • Table 184. France Migraine, by Application USD Million (2027-2032)
  • Table 185. France Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 186. Italy Migraine, by Type USD Million (2027-2032)
  • Table 187. Italy Migraine, by Application USD Million (2027-2032)
  • Table 188. Italy Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 189. United Kingdom Migraine, by Type USD Million (2027-2032)
  • Table 190. United Kingdom Migraine, by Application USD Million (2027-2032)
  • Table 191. United Kingdom Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 192. Netherlands Migraine, by Type USD Million (2027-2032)
  • Table 193. Netherlands Migraine, by Application USD Million (2027-2032)
  • Table 194. Netherlands Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 195. Rest of Europe Migraine, by Type USD Million (2027-2032)
  • Table 196. Rest of Europe Migraine, by Application USD Million (2027-2032)
  • Table 197. Rest of Europe Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 198. MEA Migraine, by Country USD Million (2027-2032)
  • Table 199. MEA Migraine, by Type USD Million (2027-2032)
  • Table 200. MEA Migraine, by Application USD Million (2027-2032)
  • Table 201. MEA Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 202. Middle East Migraine, by Type USD Million (2027-2032)
  • Table 203. Middle East Migraine, by Application USD Million (2027-2032)
  • Table 204. Middle East Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 205. Africa Migraine, by Type USD Million (2027-2032)
  • Table 206. Africa Migraine, by Application USD Million (2027-2032)
  • Table 207. Africa Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 208. North America Migraine, by Country USD Million (2027-2032)
  • Table 209. North America Migraine, by Type USD Million (2027-2032)
  • Table 210. North America Migraine, by Application USD Million (2027-2032)
  • Table 211. North America Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 212. United States Migraine, by Type USD Million (2027-2032)
  • Table 213. United States Migraine, by Application USD Million (2027-2032)
  • Table 214. United States Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 215. Canada Migraine, by Type USD Million (2027-2032)
  • Table 216. Canada Migraine, by Application USD Million (2027-2032)
  • Table 217. Canada Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 218. Mexico Migraine, by Type USD Million (2027-2032)
  • Table 219. Mexico Migraine, by Application USD Million (2027-2032)
  • Table 220. Mexico Migraine, by Distribution Channels USD Million (2027-2032)
  • Table 221. Research Programs/Design for This Report
  • Table 222. Key Data Information from Secondary Sources
  • Table 223. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Migraine: by Type USD Million (2019-2024)
  • Figure 5. Global Migraine: by Application USD Million (2019-2024)
  • Figure 6. Global Migraine: by Distribution Channels USD Million (2019-2024)
  • Figure 7. South America Migraine Share (%), by Country
  • Figure 8. Asia Pacific Migraine Share (%), by Country
  • Figure 9. Europe Migraine Share (%), by Country
  • Figure 10. MEA Migraine Share (%), by Country
  • Figure 11. North America Migraine Share (%), by Country
  • Figure 12. Global Migraine share by Players 2024 (%)
  • Figure 13. Global Migraine share by Players (Top 3) 2024(%)
  • Figure 14. Global Migraine share by Players (Top 5) 2024(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Amgen Inc. (United States) Revenue: by Geography 2024
  • Figure 18. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. AstraZeneca (United Kingdom) Revenue: by Geography 2024
  • Figure 20. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2024
  • Figure 22. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2024
  • Figure 24. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis AG (Switzerland) Revenue: by Geography 2024
  • Figure 26. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc. (United States) Revenue: by Geography 2024
  • Figure 28. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 29. Sanofi (France) Revenue: by Geography 2024
  • Figure 30. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Merck KGaA (Germany) Revenue: by Geography 2024
  • Figure 32. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 33. Eli Lilly and Company (United States) Revenue: by Geography 2024
  • Figure 34. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2024
  • Figure 36. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. AbbVie Inc. (United States) Revenue: by Geography 2024
  • Figure 38. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Gilead Sciences, Inc. (United States) Revenue: by Geography 2024
  • Figure 40. Global Migraine: by Type USD Million (2027-2032)
  • Figure 41. Global Migraine: by Application USD Million (2027-2032)
  • Figure 42. Global Migraine: by Distribution Channels USD Million (2027-2032)
  • Figure 43. South America Migraine Share (%), by Country
  • Figure 44. Asia Pacific Migraine Share (%), by Country
  • Figure 45. Europe Migraine Share (%), by Country
  • Figure 46. MEA Migraine Share (%), by Country
  • Figure 47. North America Migraine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Amgen Inc. (United States)
  • AstraZeneca (United Kingdom)
  • Bristol-Myers Squibb Company (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Sanofi (France)
  • Merck KGaA (Germany)
  • Eli Lilly and Company (United States)
  • Johnson & Johnson Services, Inc. (United States)
  • AbbVie Inc. (United States)
  • Gilead Sciences, Inc. (United States)
Additional players considered in the study are as follows:
Alder Biopharmaceuticals (United States) , BioHaven Pharmaceutical Holding Company Ltd. (United States) , AOBiome therapeutics (United States) , Allodynic therapeutics (United States) , Zosano Pharma Corp (United States)
Select User Access Type

Key Highlights of Report


Jul 2023 242 Pages 62 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Migraine Quantitative research analysis
Global Migraine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Amgen Inc. (United States), AstraZeneca (United Kingdom), Bristol-Myers Squibb Company (United States), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (United States), Sanofi (France), Merck KGaA (Germany), Eli Lilly and Company (United States), Johnson & Johnson Services, Inc. (United States), AbbVie Inc. (United States) and Gilead Sciences, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The Increased Prescription of Calcitonin Gene-Related Peptide (CGRP) Antagonists, Gepants, and Monoclonal Antibodies (Mabs) As a Preventive Migraine Treatment" is seen as one of major influencing trends for Migraine Market during projected period 2024-2032.
The Migraine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Migraine Report?

Have a Query? Click Here

Other Related Reports

Oral Cancer Treatment Comprehensive Study by Type (Squamous Cell Carcinoma, Verrucous Carcinoma, Minor Salivary Gland Carcinomas, Lymphomas, Others), Application (Hospitals & Clinics, Research Organi...
$ 3450
Pet Dietary Supplements Comprehensive Study by Type (Glucosamine, Omega 3 Fatty Acids, Probiotics & Prebiotics, Multivitamins, Antioxidants, Proteins & Peptides, Others), Application (Joint-health, S...
$ 3750
Supportive Insoles Comprehensive Study by Type (Custom Moulded, 3D Printed, Pre-Fabricated), Application (Diabetics Patients, Rheumatoid Arthritis Patients, Obesity Patients), Distribution Channel (O...
$ 3450
Smart Hospital Comprehensive Study by Type (Hardware, Services, Systems & Software), Application (General and Specialty Consultation, Medications, Others), Functionality (Remote Medicine Management M...
$ 3750
Fluoride Varnish Comprehensive Study by Application (General Hospitals, Dental Hospitals, Childs Teeth, Dental Practice), Type (Unit Dose ≥0.40 ml, Unit Dose ＜0.40 ml) Players and Region...
$ 3500
Medical Emergency Response System Comprehensive Study by Type (In-home Medical Alert Systems, Mobile medical Alert Systems), Connection Type (Wired, Wireless), End-User (Home-Based Users, Senior Care...
$ 3800